Glucocorticoid safety for treating rheumatoid arthritis

Bibliography

• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509
   PubMed Web of Science ®Google Scholar
• Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156(5):329-39
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007(1):CD006356
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52(11):3381-90
   PubMed Web of Science ®Google Scholar
• van Everdingen AA, Jacobs JWG, Siewertsz Van Reesema DR, Bijlsma JWJ. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136(1):1-12
   PubMed Web of Science ®Google Scholar
• Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350(9074):309-18
   PubMed Web of Science ®Google Scholar
• Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333(3):142-6
   PubMed Web of Science ®Google Scholar
• Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61(8):718-22
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69(6):1015-21
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000;43(3):522-30
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Scientific group on the assessment of osteoporosis at primary health care level - Summary Meeting Report Brussels, Belgium, 5–7 May 2004. 2004 May 5
   Google Scholar
• Van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(10):3104-12
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HGM, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. June, 2000. J Bone Miner Res 2005;20(8):1487-94
   PubMedGoogle Scholar
• De Vries F, Bracke M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007;56(1):208-14
   PubMed Web of Science ®Google Scholar
• Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008;67(6):823-8
   PubMed Web of Science ®Google Scholar
• Vis M, Guler-Yuksel M, Lems WF. Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int 2013;24(10):2541-53
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011;78(1):23-30
   PubMed Web of Science ®Google Scholar
• Boers M. [Prednisone for rheumatoid arthritis: the detriment of the doubt]. Ned Tijdschr Geneeskd 2012;155(32):A5069
   PubMedGoogle Scholar
• Walker AM. Confounding by indication. Epidemiology 1996;7(4):335-6
   PubMed Web of Science ®Google Scholar
• Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72(12):1905-13
   PubMed Web of Science ®Google Scholar
• Health Council of the Netherlands. Dietary reference intakes: calcium, vitamin D, thiamin, riboflavin, niacin, pantothenic acid, and biotin. Health Council of the Netherlands; The Hague: 2000; Report No.: 2000/12
   Google Scholar
• Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66(12):1560-7
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008;58(9):2612-21
   PubMed Web of Science ®Google Scholar
• Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008;59(8):1090-6
   PubMed Web of Science ®Google Scholar
• del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014;66(2):264-72
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59(12):1690-7
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69(11):1913-19
   PubMed Web of Science ®Google Scholar
• Hafstrom I, Rohani M, Deneberg S, et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis–a randomized study. J Rheumatol 2007;34(9):1810-16
   PubMed Web of Science ®Google Scholar
• Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004;63(7):797-803
   PubMed Web of Science ®Google Scholar
• Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol 1998;37(9):930-6
   PubMedGoogle Scholar
• Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47(1):72-5
   PubMed Web of Science ®Google Scholar
• Den Uyl D, van Raalte DH, Nurmohamed MT, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 2012;64(3):639-46
   PubMed Web of Science ®Google Scholar
• Pincus T, Sokka T, Castrejon I, Cutolo M. Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthr Care Res 2013;65(5):729-36
   Web of Science ®Google Scholar
• Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011;70(11):1887-94
   PubMed Web of Science ®Google Scholar
• Landewe RBM, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46(2):347-56
   PubMed Web of Science ®Google Scholar
• van Tuyl LHD, Boers M, Lems WF, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010;69(5):807-12
   PubMed Web of Science ®Google Scholar
• van Tuyl LHD, Plass AMC, Lems WF, et al. Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. Rheumatology (Oxford) 2008;47(10):1571-6
   PubMed Web of Science ®Google Scholar
• van Tuyl LHD, Plass AM, Lems WF, et al. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 2007;66(7):974-6
   PubMed Web of Science ®Google Scholar